PMID- 38207206
OWN - NLM
STAT- MEDLINE
DCOM- 20240222
LR  - 20240222
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Print)
IS  - 2473-9529 (Linking)
VI  - 8
IP  - 4
DP  - 2024 Feb 27
TI  - MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European 
      retrospective study.
PG  - 968-977
LID - 10.1182/bloodadvances.2023010704 [doi]
AB  - Large B-cell lymphoma (LBCL) carrying MYC rearrangement, alone or together with 
      BCL2 and/or BCL6 translocations, have shown a poor prognosis when treated with 
      rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone 
      (R-CHOP) in the HIV population. Scanty data are available on the prevalence and 
      prognostic impact of MYC rearrangements in HIV-associated LBCL. We conducted a 
      retrospective study to evaluate the clinical effect of MYC rearrangement in 
      HIV-associated LBCL. We evaluated clinical characteristics, treatment received, 
      and outcome of LBCL in patients with HIV with MYC rearrangement (MYC+) and 
      without MYC rearrangement (MYC-). A total of 155 patients with HIV who had 
      received fluorescence in situ hybridization analysis for MYC were enrolled in 11 
      European centers: 43 with MYC+ and 112 MYC-. Among patients with MYC, 10 had 
      double-/triple-hit lymphomas, and 33 had isolated MYC rearrangement (single-hit 
      lymphoma). Patients with MYC+ had more frequently advanced stage, >2 extranodal 
      site at presentation, and higher proliferative index. There were no significant 
      differences in overall survival and progression-free survival (PFS) between the 2 
      groups. However, patients with MYC+ received more frequently intensive 
      chemotherapy (iCT) (44%) than (R)CHOP alone (35%) or infusional treatment 
      (DA-EPOCH-R and R-CDE) (19%). Among patients with MYC+, those who received iCT 
      achieved a better outcome than patients who received nonintensive treatment 
      (complete remission, 84% vs 52%; P = .028; 5-year PFS, 66% vs 36%; P = .021). Our 
      retrospective results suggest that HIV-associated LBCL with MYC+ could be 
      considered for an intensive therapeutic approach whenever possible, whereas 
      (R)CHOP seems to give inferior results in this subset of patients in terms of 
      complete remission and PFS.
CI  - (c) 2024 by The American Society of Hematology. Licensed under Creative Commons 
      Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), 
      permitting only noncommercial, nonderivative use with attribution. All other 
      rights reserved.
FAU - Pagani, Chiara
AU  - Pagani C
AD  - Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
FAU - Rusconi, Chiara
AU  - Rusconi C
AD  - Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 
      Italy.
FAU - Dalla Pria, Alessia
AU  - Dalla Pria A
AD  - National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, 
      United Kingdom.
FAU - Ravano, Emanuele
AU  - Ravano E
AD  - Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, 
      Italy.
FAU - Schommers, Philipp
AU  - Schommers P
AUID- ORCID: 0000-0003-3375-6800
AD  - Department of Internal Medicine, Medical Faculty and University Hospital Cologne, 
      University of Cologne, Cologne, Germany.
FAU - Bastos-Oreiro, Mariana
AU  - Bastos-Oreiro M
AD  - Hematology Department, Hospital General Universitario Gregorio Maranon, Madrid, 
      Spain.
FAU - Verga, Luisa
AU  - Verga L
AD  - Division of Hematology, Azienda Ospedaliera San Gerardo, Monza, Italy.
FAU - Gini, Guido
AU  - Gini G
AD  - Division of Hematology, Azienda Ospedaliera Universitaria Ospedali Riuniti, 
      Ancona, Italy.
FAU - Spina, Michele
AU  - Spina M
AD  - Medical Oncology Division, Centro Riferimento Oncologico, Aviano, Italy.
FAU - Arcaini, Luca
AU  - Arcaini L
AD  - Department of Molecular Medicine, University of Pavia, Pavia, Italy.
AD  - Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
FAU - Steffanoni, Sara
AU  - Steffanoni S
AD  - Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
FAU - Dalu, Davide
AU  - Dalu D
AUID- ORCID: 0000-0002-8017-2149
AD  - Department of Oncology, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, 
      Italy.
FAU - Crucitti, Lara
AU  - Crucitti L
AD  - Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, 
      Italy.
FAU - Lorenzi, Luisa
AU  - Lorenzi L
AUID- ORCID: 0000-0003-2483-2955
AD  - Pathology Unit, ASST Spedali Civili di Brescia and Department of Molecular and 
      Translational Medicine, University of Brescia, Brescia, Italy.
FAU - Balzarini, Piera
AU  - Balzarini P
AD  - Pathology Unit, ASST Spedali Civili di Brescia and Department of Molecular and 
      Translational Medicine, University of Brescia, Brescia, Italy.
FAU - Cattaneo, Chiara
AU  - Cattaneo C
AUID- ORCID: 0000-0003-0031-3237
AD  - Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
FAU - Bongiovanni, Lucia
AU  - Bongiovanni L
AD  - Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
AD  - Universita Vita-Salute San Raffaele, Milan, Italy.
FAU - Rosenwald, Andreas
AU  - Rosenwald A
AD  - Institute of Pathology, University of Wurzburg, and Comprehensive Cancer Center 
      Mainfranken, Wurzburg, Germany.
FAU - Facchetti, Fabio
AU  - Facchetti F
AD  - Pathology Unit, ASST Spedali Civili di Brescia and Department of Molecular and 
      Translational Medicine, University of Brescia, Brescia, Italy.
FAU - Bower, Mark
AU  - Bower M
AUID- ORCID: 0000-0002-4077-6351
AD  - National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, 
      United Kingdom.
FAU - Ferreri, Andres J M
AU  - Ferreri AJM
AUID- ORCID: 0000-0001-9606-6124
AD  - Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
AD  - Universita Vita-Salute San Raffaele, Milan, Italy.
FAU - Rossi, Giuseppe
AU  - Rossi G
AD  - Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
FAU - Tucci, Alessandra
AU  - Tucci A
AUID- ORCID: 0000-0003-3052-7463
AD  - Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
FAU - Re, Alessandro
AU  - Re A
AUID- ORCID: 0000-0003-1156-6395
AD  - Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 0 (MYC protein, human)
SB  - IM
MH  - Humans
MH  - Cyclophosphamide/therapeutic use
MH  - *HIV Infections/drug therapy/epidemiology
MH  - In Situ Hybridization, Fluorescence
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Proto-Oncogene Proteins c-myc/genetics
MH  - Retrospective Studies
MH  - Rituximab/therapeutic use
MH  - Vincristine/therapeutic use
PMC - PMC10877133
COIS- Conflict-of-interest disclosure: M.S. reports honoraria from Gilead, Servier, 
      Novartis, Incyte, BeiGene, and Istituto Gentili; and research funding from 
      Menarini. L.A. reports consultancy fees from or advisory role in Roche, 
      Janssen-Cilag, Verastem, Incyte, EUSA Pharma, Celgene/Bristol Myers Squibb, 
      Kite/Gilead, and ADC Therapeutics; speakers' bureau fees from EUSA Pharma and 
      Novartis; and research funding from Gilead Sciences. D.D. reports travel grants 
      from Roche, Gentili, Lilly, and Eisai; and other remuneration from Gentili and 
      Daikii Sanchio. The remaining authors declare no competing financial interests.
EDAT- 2024/01/11 18:42
MHDA- 2024/02/19 06:43
PMCR- 2024/01/13
CRDT- 2024/01/11 15:33
PHST- 2023/12/29 00:00 [accepted]
PHST- 2023/05/15 00:00 [received]
PHST- 2024/02/19 06:43 [medline]
PHST- 2024/01/11 18:42 [pubmed]
PHST- 2024/01/11 15:33 [entrez]
PHST- 2024/01/13 00:00 [pmc-release]
AID - 507116 [pii]
AID - 10.1182/bloodadvances.2023010704 [doi]
PST - ppublish
SO  - Blood Adv. 2024 Feb 27;8(4):968-977. doi: 10.1182/bloodadvances.2023010704.